Pharmaceutical research and development is experiencing a profound transformation, marked by an unprecedented convergence of technological advancements, vast data streams, and deeper biological understanding. This shift is fundamentally altering how new medicines are discovered and brought to patients, moving beyond the traditional "small molecule versus biologic" dichotomy to embrace a more integrated, hybrid landscape of therapeutic modalities.
A Shifting Market Landscape: Small Molecules Endure, Biologics Surge
The global pharmaceutical market has seen significant growth and a dynamic rebalancing between its two primary drug classes. In 2018, the market was valued at an estimated $828 billion, with small molecules accounting for 69% of sales and biologics for 31%. By 2023, the market had expanded to $1344 billion, with the small molecule share decreasing to 58% and biologics rising to 42%. This rapid growth in biologics, three times faster than small molecules, has led some analysts to project that biologics sales could surpass small molecule sales as early as 2027, signaling a significant evolution in therapeutic preferences and capabilities.
Despite the impressive growth trajectory of biologics, small molecules continue to demonstrate remarkable resilience and innovation. In a testament to their enduring value, small molecules constituted 62% of novel drug approvals by the FDA in 2024 and an even higher 72% in early 2025. This persistence is not merely a legacy effect but is actively driven by a "technological upgrade" fueled by advancements in AI-accelerated discovery, novel chemical approaches, and breakthroughs in oral delivery, as noted by Murray Aitken in IQVIA’s 2024 data. While biologics are undeniably driving significant market value, small molecules are undergoing a renaissance, adapting and expanding their therapeutic reach.
The Era of Precision Medicine and AI-Driven Discovery
A defining characteristic of the current R&D inflection point is the decisive shift from broad-spectrum drug approaches to highly targeted precision medicine. This evolution is underpinned by significant advances in genomics, sophisticated target biology, and the transformative power of artificial intelligence. Researchers are now equipped to identify and address diseases with unprecedented specificity, moving away from generalized interventions.
Andreas Mattern, Vice President of Professional Services at Elsevier, encapsulates this transition, stating, "It’s no longer trying to shotgun blast a whole bunch of things, but instead trying to sniper and be really tight in what we’re attacking." This philosophy underscores a strategic front-loading of biological intelligence in the drug discovery process. Pharmaceutical companies are increasingly prioritizing a deep understanding of the target, its genomic context, and the specific patient population before committing to a particular therapeutic modality. This data-driven approach aims to optimize the chances of success early on.
Artificial intelligence stands at the forefront of this revolution, compressing timelines, generating novel hypotheses, and profoundly influencing modality selection. Advanced AI tools like AlphaFold for protein structure prediction, generative chemistry for designing new molecules, and large language models for insights extraction are being layered onto vast proprietary and public datasets. This integration unlocks new insights, streamlines discovery, and fundamentally changes the speed and efficiency of drug development.
Daphne Koller, CEO and founder of Insitro, highlighted the critical role of AI at the Danaher Summit: "Most programs fail in the clinic because of the early stages of the decision-making process. The focus of the next few years needs to be on increasing the success rate (the yield), rather than just efficiency. AI must help us select the right therapeutic hypotheses and the right patient populations from the start." This emphasizes that AI’s greatest impact may lie not just in accelerating processes, but in dramatically improving the strategic foundations of drug development.
Defining the Modalities: Small, Large, and the Emerging Hybrids
To understand the convergence, it’s crucial to delineate the characteristics of traditional small and large molecules.
Small Molecules: These are chemically synthesized compounds, typically characterized by molecular weights below 900 Daltons. Their relatively compact size allows them to readily cross cell membranes, granting access to intracellular targets. Key advantages include oral bioavailability (allowing for pill-form administration), stability at room temperature, and manufacturability at scale. They also benefit from well-established regulatory and manufacturing pathways, contributing to a lower cost of goods. Historically, small molecules have formed the bedrock of pharmaceutical innovation.
Large Molecules (Biologics): Derived from living organisms, these include complex structures like proteins, nucleic acids, and even entire cells. They are significantly larger than small molecules, generally weighing over 1,000 Daltons. Due to their size, biologics typically cannot easily traverse cell membranes, often necessitating administration via injection or infusion. Examples encompass monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), mRNA therapies, CAR-T cell therapies, and engineered peptides such as GLP-1 agonists. While highly specific to their targets, minimizing off-target toxicity, biologics present greater manufacturing and storage complexities, often requiring cold chain logistics.
The choice between these modalities is fundamentally dictated by target biology. Factors such as target specificity, the intended patient population, and whether the target resides intracellularly or extracellularly are paramount. Increasingly, sophisticated data platforms are central to answering these complex questions, aggregating published research, clinical trial data, and pipeline intelligence to inform strategic decisions. Mattern clarifies, "The choice of modality — whether I use a small molecule or any number of the large molecules — really comes down to understanding your target, understanding the biology."
Historically, small molecules were limited to targeting proteins with well-defined binding pockets, leaving an estimated 80% of the human proteome "undruggable" by traditional means. This significant limitation was a primary catalyst for the development of biologics, which can engage targets inaccessible to conventional small molecules. However, the perceived binary distinction between small and large molecules is increasingly becoming a false dichotomy, giving way to a growing class of hybrid and intermediate modalities. These include ADCs, PROTACs (proteolysis-targeting chimeras), and RNA-small molecule conjugates, which deliberately combine advantageous properties from both categories, blurring the lines and expanding therapeutic possibilities.
A Renaissance in Small Molecule R&D
For years, the prevailing narrative suggested that biologics would gradually supplant small molecules as the dominant therapeutic modality. This perspective is now being vigorously challenged by a surge of innovation in small molecule R&D. Driven by AI-powered discovery, novel chemical approaches, and groundbreaking delivery technologies, small molecules are now reaching previously inaccessible target classes and exhibiting enhanced capabilities.
The inherent advantages of small molecules—oral bioavailability, manufacturing scalability, stability, intracellular access, and lower cost of goods—ensure their continued foundational role in medicine. "Small molecules will remain at the foundation because they’re scalable, they’re orally delivered, they’re stable," Mattern predicts. This suggests that for many indications, particularly in metabolic and infectious diseases, small molecules will remain the default and preferred therapeutic option.
One of the most transformative developments is Targeted Protein Degradation (TPD). Instead of merely inhibiting a protein’s function, degraders like PROTACs and molecular glues ingeniously hijack the cell’s own ubiquitin-proteasome system to eliminate disease-causing proteins entirely. This approach dramatically expands the "druggable" target space, making proteins that lack conventional binding pockets or are too large or flexible for traditional inhibitors now accessible. Nello Mainolfi, CEO of Kymera Therapeutics, articulated the potential: "Targeted protein degradation allows us to reach broader patient populations compared to injectable biologics. We are developing oral drugs with biologics-like activity, reaching critical signaling nodes that have been historically ‘undruggable’ with traditional inhibitors."
Another emerging frontier is RNA-targeting small molecules. Historically, RNA was considered an "undruggable" target for small molecules. However, breakthroughs in structural biology, coupled with advanced AI methodologies, are fundamentally altering this perception. These molecules are designed to bind and modulate RNA rather than proteins, offering the potential to address targets upstream of protein expression, such as transcription factors and splice sites, which are inaccessible to both traditional small molecules and most biologics. A significant commercial validation of this approach came last year when Merck Group entered into a $2 billion partnership with Skyhawk Therapeutics, specifically focusing on the discovery of RNA-targeting small molecules for neurological disorders.
Perhaps one of the most commercially impactful trends in small molecule R&D is the relentless push to achieve oral availability for complex molecules, including peptides and other structures that have historically required injection. The GLP-1 story serves as the highest-profile example. Semaglutide, initially an injectable peptide, is now available in an oral formulation, with next-generation oral small molecule GLP-1 agonists actively in development. Mattern highlights the profound implications: "If you can make complex biological drugs orally available, you expand access, you make them stable, you can deliver them to remote corners of the world without worrying about a cold chain." Oral peptide technologies hold the promise of unlocking a new generation of drugs that combine the precise targeting capabilities of biologics with the unparalleled convenience and scalability of small molecules.
Expanding the Frontier: Innovation in Large Molecule R&D
Biologics are currently undergoing an unprecedented expansion, with a pipeline that is broader, more diverse, and technically ambitious than at any previous point in pharmaceutical history. What began with the advent of monoclonal antibodies in the 1980s has blossomed into a rich ecosystem of modalities, each possessing distinct mechanisms, target classes, and utility across various patient populations.
Key advantages of biologics include their capacity for extraordinary precision in binding a single target, thereby minimizing off-target effects. Proteins, receptors, and ligands located on the cell surface or circulating in the bloodstream are highly accessible to these large molecules. Many biologics also offer long-lasting therapeutic effects, with some requiring dosing only monthly or even less frequently. From blocking a receptor to delivering a cytotoxic payload or even editing a gene, biologics offer a diverse array of mechanisms often unavailable to small molecules.
Monoclonal Antibodies (mAbs) remain the cornerstone of the biologic pipeline. Continuous engineering efforts are focused on improving their half-life, reducing immunogenicity, and enabling bispecific targeting—where antibodies are designed to engage two distinct targets simultaneously. This bispecific approach can enable novel mechanisms, such as redirecting T cells to precisely target and eliminate tumor cells.
Another pivotal large molecule class is Antibody-Drug Conjugates (ADCs), which exemplify a hybrid approach. ADCs combine the exquisite targeting precision of an antibody with the potent cytotoxic efficacy of a small molecule payload. This "guided missile" strategy delivers chemotherapy directly to cancer cells, minimizing systemic toxicity. ADCs have seen a significant wave of approvals and robust late-stage pipeline activity, with over 100 ADCs currently in global clinical development.
The RNA-based therapies space has seen explosive growth, particularly since the COVID-19 pandemic. mRNA therapies, validated by rapid vaccine development, are now being diversified into oncology vaccines, rare disease treatments, and a broader range of infectious disease vaccines. In parallel, siRNA (small interfering RNA) and ASOs (antisense oligonucleotides) represent RNA interference approaches that silence disease-causing genes at the mRNA level. These modalities have gained regulatory approvals in various rare disease and cardiovascular indications, demonstrating their power to address diseases at a genetic level.
CAR-T cell therapies utilize a patient’s own T cells, genetically engineered to recognize and destroy cancer cells. These therapies have been transformative in the treatment of hematologic malignancies, with intensive research focused on extending their application to solid tumors. Similarly, CRISPR and other gene editing technologies are rapidly advancing, with the first approved CRISPR therapy reaching patients in 2023, heralding a new era of genetic medicine.
Oncology stands as the single largest driver of R&D investment in biologics, serving as the therapeutic area where the most ambitious large molecule science is being deployed. The expansion of ADCs and immuno-oncology, including checkpoint inhibitors, CAR-T, and bispecifics, continues unabated, progressively moving from hematologic cancers into the more challenging landscape of solid tumors.
The GLP-1 Story: A Blueprint for Modality Evolution
The remarkable success of GLP-1 receptor agonists provides a compelling case study illustrating the immense commercial and scientific power of large molecule R&D, and critically, how it can catalyze innovation across small molecules. Drugs like semaglutide and tirzepatide have rapidly become some of the best-selling pharmaceuticals in history, validating peptide engineering and therapeutic efficacy on an unprecedented scale.
Beyond their direct impact, the GLP-1 story also exemplifies lifecycle innovation, where the profound clinical and commercial validation of a biologic drives subsequent small molecule development. Mattern observes, "GLP-1 is really showing how that balance is evolving. They are a peptide-based modality — technically in the large molecule category — but the commercial success is now driving innovation across small molecules: oral delivery and combination therapy." He anticipates this pattern will repeat: "Historically, many therapies start as injectables because it’s technically simpler to deliver a complicated molecule that way. But once you get the validation of the biology and the commercial demand becomes clear, there’s a really strong investment incentive to invest in more convenient formats." The journey of GLP-1 agonists, from injectable peptides to oral small molecule formulations, is likely to become a template for future modality evolution across a wide spectrum of therapeutic areas.
Strategic Implications for Stakeholders
The dynamic evolution of drug modalities carries significant implications for all stakeholders within the pharmaceutical ecosystem.
For large pharmaceutical companies, the imperative is clear: strategic portfolio diversification across the full spectrum of modalities. This necessitates substantial investment in robust data infrastructure to support AI-driven discovery and a proactive approach to strategic acquisitions or licensing of platform biotechs, ideally before their valuations fully reflect clinical validation.
For biotechnology companies, maintaining a strong platform focus remains a key differentiator. However, the most fundable and partnerable propositions will increasingly combine a novel modality with a thoroughly validated target and a clear, compelling path to oral or otherwise convenient delivery.
Investors should keenly observe advancements in drug delivery technology, paying particular attention to companies that are effectively solving the "last-mile problem" – the challenge of safely and conveniently getting complex molecules to their intended targets within the body.
For researchers and R&D teams, the fundamental shift means that the data foundation has become the new lab bench. Investing in electronic laboratory notebooks (ELNs), developing comprehensive ontologies, and implementing structured data capture from the outset are no longer optional but critical necessities for leveraging AI-powered drug discovery effectively.
Conclusion: A Future of Integrated Innovation
The perceived binary competition between small and large molecules is giving way to a more nuanced understanding. The "gray area" between these traditional modalities is rapidly expanding, transforming the modality question from a binary choice into a rich, interconnected spectrum of therapeutic possibilities.
As Mattern concludes, "I don’t see small and large molecules competing for dominance. I think there’s going to be a continued balance… small molecules will remain at the foundation because they’re scalable, they’re orally delivered, they’re stable. And biologics will probably be where we continue to expand, where things like precision and durability matter."
The most consequential change in drug discovery in a generation is the profound shift from empirical trial and error to data-driven prediction and design. Organizations that are investing heavily in data quality, robust governance, and seamless integration are best positioned to harness the full power of AI-powered drug discovery. Beyond mere scientific insight, the ultimate challenge and next frontier lie in optimizing delivery: lipid nanoparticles, oral peptide technologies, advanced ADC linker chemistry, and next-generation formulation science are poised to unlock the next wave of breakthroughs.
Ultimately, the expansion and integration of the therapeutic modality toolkit represent unequivocally good news for patients, for scientific advancement, and for the pharmaceutical industry as a whole. More diverse tools translate into the ability to address more targets, tackle a wider array of diseases, and reach more patients with effective treatments. In this evolving landscape, the true competition is not between different modalities, but between organizations that proactively embrace this growing complexity and those that fail to adapt.
Leave a Reply